E-ISSN 2250-0944
ISSN 2250-1150
doi: 10.48047/ijprt/15.02.603

Research Article

NOVEL COMBRETASTATIN A-4 ANALOGUES: ADVANCES AND INSIGHTS FROM INDIAN COMBRETACEAE PLANTS

Anshika Shukla[a], Gaurav Dubey, Ankita Srivastava

Research Scholar, NIMS University, Jaipur Rajasthan
Professor& HOD, Nims Institute of Pharmacy, NIMS University, Jaipur Rajasthan
Professor,TSM University,Lucknow

1-INTRODUCTION

Cancer remains one of the leading causes of morbidity and mortality worldwide, creating a continuous demand for anticancer agents that are both effective and selective. Among plant-derived anticancer molecules, Combretastatin A-4 (CA-4) has emerged as a significant lead compound due to its unique mechanism of action targeting tumor vasculature rather than normal dividing cells. Combretastatin A-4 is a naturally occurring stilbene-based compound originally isolated from the bark of Combretum caffrum, a tree belonging to the Combretaceae family and native to Southern Africa. Unlike conventional cytotoxic drugs, CA-4 acts primarily as a vascular disrupting agent (VDA), selectively damaging the endothelial cells of tumor blood vessels. This disruption leads to rapid cessation of blood flow within the tumor, resulting in ischemia and subsequent tumor cell death. Due to this vascular-targeted approach, CA-4 represents a novel paradigm in anticancer therapy.

1.1- COMBRETUM CAFFRUM- Although Combretum caffrum is not found in India and CA-4 is not naturally present in Indian flora, several Indian medicinal plants belonging to the same Combretaceae family have long been recognized for their therapeutic value, including anticancer and anti-angiogenic properties. These plants share a common phytochemical background rich in polyphenols, flavonoids, tannins, and triterpenoids, which are known to interfere with cancer cell proliferation and oxidative stress pathways.Prominent Indian members of the Combretaceae family include Terminalia arjuna (Arjun), Terminalia chebula (Harad/Haritaki), Terminalia bellirica (Baheda), Terminalia tomentosa (Asna/Saja), and Terminalia catappa (Jangli Badam). These plants have been widely used in traditional medicine systems such as Ayurveda and have demonstrated anticancer-related activities including antioxidant action, inhibition of tumor cell growth, induction of apoptosis, and suppression of angiogenesis.

However, their effects are generally broad and supportive, arising from complex mixtures of phytochemicals rather than from a single, highly specific active molecule.In contrast, Combretastatin A-4 represents a well-defined, target-specific anticancer compound with a clearly established molecular mechanism involving tubulin binding and vascular disruption. Despite its promising anticancer efficacy, the clinical

development of CA-4 has been hindered by certain intrinsic limitations, such as poor aqueous solubility, chemical instability due to cis-trans isomerization, rapid metabolic degradation, and dose-related toxicity. These challenges restrict its therapeutic application in its native form.

To overcome these drawbacks, significant research efforts have been directed toward the design and development of novel Combretastatin A-4 analogs. Structural modification of the CA-4 scaffold aims to enhance its chemical stability, improve bioavailability, reduce toxicity, and increase selectivity toward tumor tissues. Novel CA-4 derivatives also allow better compatibility with advanced drug delivery systems such as liposomes, nanoparticles, and polymeric carriers, further enhancing therapeutic outcomes.

Thus, while Indian Combretaceae plants provide valuable insights into the anticancer potential of this plant family, Combretastatin A-4 remains the most potent and mechanistically precise representative. The transformation of CA-4 into novel analogs is essential for translating its remarkable biological activity into clinically viable anticancer therapeutics. This research-based evolution from a natural lead compound to optimized novel analogs highlights the importance of CA-4 in modern anticancer drug discovery.

2- RESEARCH PROBLEM

Cancer continues to pose a significant global health burden, creating a pressing need for selective and effective anticancer agents. Combretastatin A-4 (CA-4), a naturally occurring stilbene from Combretum species, has gained attention for its unique ability to target tumor blood vessels selectively. However, its therapeutic potential is constrained by poor solubility, chemical instability, and rapid metabolism. Indian Combretaceae species, which are rich in diverse bioactive compounds, represent a largely untapped source for the development of novel CA-4 analogues. Exploring these plants can provide crucial insights for designing derivatives with enhanced stability, improved bioavailability, and superior anticancer efficacy, thereby advancing the search for clinically viable anticancer therapies.

2.1- RESEARCH GAP

Although CA-4 demonstrates impressive anticancer effects, several critical gaps remain:

1. Toxicity Issues: Dose-dependent cardiovascular and systemic toxicities limit its clinical potential. Research on analogues that reduce toxicity while preserving anticancer activity is insufficient.
2. Indian Plant-Derived Insights: Indian members of the Combretaceae family, including Terminalia arjuna (Arjun), T. chebula (Harad), and T. bellirica (Baheda), contain polyphenolic compounds with anticancer and anti-angiogenic properties. However, their potential as templates for designing novel CA-4 analogues remains underexplored.
3. Structure-Activity Relationship Studies: Comprehensive studies on rational structural modifications to improve potency, tumor selectivity, and pharmacokinetic profiles are limited.

Despite CA-4's well-documented anticancer potential, its clinical translation is hindered by stability, solubility, metabolic, and toxicity issues. Combined with the underexplored potential of Indian Combretaceae phytochemicals, there is a strong scientific need to design, optimize, and evaluate novel CA-4 analogues with improved pharmacological and therapeutic properties.

3- RESEARCH OBJECTIVE

Combretastatin A-4 (CA-4) is a potent natural stilbene known for its anticancer activity through inhibition of tubulin polymerization. Despite its therapeutic promise, limitations such as poor solubility and metabolic instability have motivated the development of novel analogues. Indian Combretaceae plants, rich in diverse phytochemicals, represent an underexplored resource for discovering new CA-4 derivatives with enhanced efficacy and drug-like properties. In this context, the following objective are formulated to guide the study:

"

a0ceae species for their potential as sources of novel Combretastatin A-4 analogues, highlighting their prospective applications in anticancer drug development.

The objective focuses on the phytochemical potential of Indian Combretaceae species, aiming to provide insights that could guide the design and synthesis of new CA-4 analogues with improved pharmacological properties.

4- COMPARATIVE STUDY OF INDIAN COMBRETACEAE PLANTS FOR CA-4 ANALOGUES :MODIFICATION

4.1- Phytochemical Potential of Indian Combretaceae Species

The Combretaceae family, widely distributed across India, comprises several species traditionally used in medicine. These plants are rich in bioactive compounds, including flavonoids, tannins, phenolics, and terpenoids. Such compounds have been associated with antioxidant, cytotoxic, and anticancer properties, making them attractive candidates for research into novel anticancer agents.

Key species and their bioactive components:

Plant Species (Scientific Name)	Major Phytochemicals	Relevance to Cancer Research
Terminalia arjuna Roxb.	Tannins (casuarinin), flavonoids (luteolin), triterpenoids (arjunolic acid), phenolics (gallic & ellagic acids)	Shows cytotoxicity and antioxidant activity; compounds may help in designing analogues with improved anticancer properties.

Combretum indicum (L.)	Alkaloids, flavonoids, terpenoids, phenols	Exhibits moderate cytotoxic activity; stilbene-like compounds can inspire CA-4 derivative design.
Terminalia chebula Retz.	Hydrolysable tannins, phenolics	Known for antioxidant and cytotoxic effects; potential scaffold for anticancer compound developmen
Combretum albidum	Polyphenols, tannins	Limited anticancer studies, but offers bioactive templates for synthetic modifications.

Insight: Although these plants do not naturally contain Combretastatin A-4, their phytochemicals can provide valuable leads for developing novel CA-4 analogues with improved efficacy and stability.

4.2- Synthetic Combretastatin A-4 Analogues and Their Advancements

Combretastatin A-4 (CA-4) is a natural stilbene that inhibits tubulin polymerization, disrupting microtubule dynamics in cancer cells. Despite its potent anticancer activity, its clinical use is limited by poor solubility and chemical instability, as well as rapid conversion from the active cis-form to a less active trans-form. To overcome these challenges, researchers have developed synthetic analogues with chemical modifications aimed at enhancing solubility, stability, and anticancer potency.

Examples of CA-4 analogue modifications:

Analogue Type	**Modification**	**Effect on Activity**
3’-O substituted ethers	Modification of the 3’-hydroxy group	Improved cytotoxicity and tubulin binding
Quinoline-based analogues	Replacement of ring B with quinoline	Enhanced potency and selectivity against cancer cells

Piperazine or cyano-stilbenes	Addition of polar groups	Increased aqueous solubility without reducing anticancer activity
Heterocyclic derivatives	Incorporation of triazole or thiol moieties	Strong cytotoxicity and apoptotic induction
Cyclic CA-4 analogues	Replacement of the ethene bridge with cyclic or amide linkers	Greater chemical stability with retained antiproliferative effect

4.3- Comparative Perspective: Plants vs Synthetic CA-4 Analogues

Feature	**Indian Combretaceae Plants**	**Synthetic CA-4 Analogues**
Source	Natural extracts	Chemically synthesized
Major Compounds	Flavonoids, phenols, tannins, terpenoids	Stilbene core with bridge or ring modifications
Anticancer Activity	Moderate cytotoxicity and antioxidant effects	Potent tubulin inhibition, nanomolar IC_{50} activity
Relation to CA-4	Indirect, via lead inspiration	Direct, based on CA-4
Application	Scaffold for designing new molecules	Preclinical and SAR studies for anticancer drugs

Insight: Indian Combretaceae species offer a rich chemical diversity that can guide the design of novel CA-4 analogues. By integrating natural product insights with synthetic modifications, it is possible to develop more stable, bioavailable, and potent anticancer compounds.

4.4. Chemical Structure Reference

A- Combretastatin A-4 (CA-4) Core Structure:

OCH3 OCH3

\ /

Ph — C=C — Ph

/ \

OCH3(3,4,5)

B- Flavonoid core (e.g., Quercetin):

OH OH

\ /

C6 — C3 — C6

/ \

OH OH

C. Proposed Hybrid Design:

Connect the B ring of CA-4 via a flexible linker (e.g., ester, amide, or alkyl chain) to the A or C ring of the flavonoid. This maintains the tubulin-binding pharmacophore of CA-4 while introducing antioxidant and apoptotic functionality from the flavonoid.

Textual representation:

CA-4 core — linker (e.g., -CO-NH-) — flavonoid core

D- Rationale:

CA-4 provides tubulin inhibition.

Flavonoid provides apoptosis induction, ROS modulation, and antioxidant activity.

The hybrid may improve solubility, selectivity, and overall anticancer efficacy.

Key Sites for Modification:

1. Cis double bond (bridge) – replacement with cyclic or amide linkers to prevent isomerization.

2. Ring B substitutions – quinoline, triazole, or other heterocycles to enhance potency.

3. Polar group addition – cyano, amine, or piperazine groups to improve solubility and pharmacokinetics.

Indian Combretaceae plants, such as Terminalia arjuna and Combretum indicum, are promising sources of bioactive compounds that can inspire the design of novel CA-4 analogues. While these plants do not naturally contain CA-4, their flavonoids, phenolics, and stilbene-like structures can serve as scaffolds or templates. Combining these natural insights with synthetic chemical modifications provides a strategic pathway for developing more effective, stable, and selective anticancer agents.

5- CONCLUSION

Combretastatin A-4 (CA-4) has demonstrated remarkable anticancer potential due to its selective disruption of

tumor vasculature. However, its clinical application is limited by poor solubility, chemical instability, and rapid metabolic degradation. This study emphasizes the opportunity to develop novel CA-4 analogues by leveraging the rich phytochemical diversity of Indian Combretaceae plants. Bioactive compounds such as flavonoids, phenolics, tannins, and stilbene-like molecules from species like Terminalia arjuna, Combretum indicum, and Terminalia chebula exhibit structural similarities to CA-4, making them suitable scaffolds for chemical modification or hybrid molecule design.

The comparative study revealed that while these plants do not naturally produce CA-4, their constituents can inspire the development of analogues that combine CA-4's tubulin inhibitory activity with additional anticancer mechanisms, such as apoptosis induction and antioxidant effects. In addition, other plant-derived compounds, such as curcumin from raw turmeric (Curcuma longa), may be explored in future research. Curcumin and related natural compounds could be integrated into hybrid structures or serve as chemical modifiers to enhance solubility, stability, or selectivity, potentially creating multi-functional anticancer agents.

By bridging natural product chemistry with synthetic modifications—like heterocyclic substitution, bridge stabilization, and polar functional group incorporation—researchers can develop next-generation CA-4 derivatives with improved pharmacokinetics, potency, and safety. Overall, Indian Combretaceae plants, together with other phytochemicals such as turmeric, offer untapped potential for rational design of novel anticancer agents, paving the way for future studies that translate natural and synthetic insights into clinically effective therapies.

So that research find the scope of new development concept "Phytochemical-Integrated Combretastatin Analogue (PICA) Concept"

i. **Hybrid Principle of Natural Products and CA-4**

Indian Combretaceae plants contain bioactive compounds such as flavonoids, tannins, and phenolics that share structural features with CA-4.

This gives rise to a new principle: CA-4 can be hybridized with these natural compounds to create a novel molecule that is potentially more stable, soluble, and effective.

Example: CA-4 + Curcumin (from turmeric) hybrid → combines tubulin inhibition with antioxidant and apoptosis-inducing effects.

ii. **Combination and Synergistic Principle**

The co-delivery or chemically modified hybrid of Curcumin and CA-4 can produce enhanced anticancer effects in tumor cells.

This principle suggests that natural compounds are not merely supportive, but can act as active enhancers of CA-4's pharmacological activity.

iii. **Nature-Inspired Modified Drug Principle**

Chemical modifications inspired by Indian plant bioactives can lead to the creation of synthetic CA-4 analogues.This approach can improve potency and stability, while also enhancing drug selectivity and safety profile.

The new concept emerging from today's discussion is that:

Conceptual Hybrid Molecule



1. **CA-4 Core** → Responsible for tumor blood vessel disruption and tubulin polymerization inhibition.
2. **Linker** → A chemical bridge (amide, ester, or alkyl chain) that connects CA-4 to the plant compound and stabilizes the hybrid structure.
3. **Curcumin-like Moiety** → Provides additional anticancer effects, such as apoptosis induction, antioxidant activity, and improved solubility.
4. **Hybrid Molecule Outcome** → Combines the synthetic anticancer activity of CA-4 with the natural bioactive properties of plant compounds, potentially resulting in a more potent, stable, and selective anticancer agent.

"By utilizing bioactive compounds from Indian plants, novel CA-4 hybrids or modified analogues can be developed, overcoming the traditional limitations of CA-4 such as poor solubility, instability, and toxicity, and potentially providing more effective anticancer therapies."

REFRENCES

1-Pettit, G. R.,Isolation and structure of combretastatin A-4, a potent inhibitor of microtubule assembly. Journal of Medicinal Chemistry, 1989, 32(11), 2393–2397.

2-Tozer, G. M., Combretastatin A-4 phosphate as a tumor vascular-targeting agent.Cancer Research, 2002, 62, 7247–7253.

3-Lin, C. M.,Inhibition of tubulin polymerization by combretastatin A-4.Biochemical Pharmacology, 1989, 38, 4413–4420.

4-Hori, K.,Biological and pharmacological limitations of combretastatin A-4.British Journal of Cancer, 1999, 80, 178–183.

5-Tron, G. C., Medicinal chemistry of combretastatin A-4: Development of novel analogues.Journal of Medicinal Chemistry, 2006, 49, 3033–3044.

6-Kumar, S., & Pandey, A. K.,Chemistry and biological activities of flavonoids from Terminalia species. Pharmacognosy Reviews, 2013, 7, 152–160.

7-Dwivedi, S., Terminalia arjuna: A cardioprotective and anticancer medicinal plant.Journal of Ethnopharmacology, 2007, 114, 114–129.

8-Saleem, A.,Anticancer activity of Terminalia chebula extracts.Phytotherapy Research, 2002, 16, 65–68.

9-Cock, I. E.,The medicinal properties and phytochemistry of plants of the Combretaceae family.Pharmacognosy Communications, 2015, 5, 67–83.

10-. IJSRST. "Phytochemical Analysis of Combretaceae Species." Link - https://ijsrst.com/IJSRST218244?utm

11. African Journal of Biomedical Research. "Anticancer Potential of Combretum indicum Extracts." Link- https://africanjournalofbiomedicalresearch.com/index.php/AJBR/article/view/7888?utm_

12- PubMed. "Phytochemistry and Pharmacology of Terminalia arjuna." Link - https://pubmed.ncbi.nlm.nih.gov/36933876/

13- PMC. "Phytochemistry and pharmacology of Terminalia arjuna." Link - https://pmc.ncbi.nlm.nih.gov/articles/PMC3805097/

14. BMC Chemistry. "CA-4 derivatives: synthesis and structure-activity relationship studies." Link- https://link.springer.com/article/10.1186/1752-153X-7-179

15- MDPI. "Quinoline-based CA-4 analogues with enhanced anticancer activity." Link-https://www.mdpi.com/1424-8247/13/11/393

16- PubMed. "Advances in Combretastatin A-4 analogue research." Link- https://pubmed.ncbi.nlm.nih.gov/36838705/

17. PubMed Central. "Piperazine and cyano modifications for improved CA-4 solubility." Link- https://pmc.ncbi.nlm.nih.gov/articles/PMC9963121/

18- Ponraj, P., & Rajendran, S. (2024). Design and synthesis of a novel curcumin–combretastatin A-4 molecular skeleton: two pharmacophores. RSC Advances, 14, 37227–37233.

(This study reports the design and synthesis of a hybrid molecule that integrates the structural features of both CA-4 and curcumin, aiming to improve pharmacokinetic and anticancer properties by combining two bioactive natural product scaffolds.)